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Background: Ventilatory impairment is known to occur in patients with heart failure (HF). Alveolar volume (VA) is
measured by the dilution of an inert gas during a single breath-hold maneuver. Such measurement is sensitive to
ventilatory disturbances. We conducted a prospective, observational study to establish the prognostic value of VA
in systolic HF.
Methods: We studied 260 consecutive patients who were hospitalized for systolic HF. All patients were evaluated
under stable clinical conditions, before hospital discharge. Lung function studies included spirometry and
determination of the lung diffusing capacity for carbon monoxide (DLCO) by the single-breath method. We
also measured the cardiothoracic ratio on frontal chest radiographs, and the circulating levels of N-terminal
pro-hormone of B-type natriuretic peptide (NT-proBNP). The hazard ratio (HR) of death was estimated with Cox
regression, and the percentiles of survival time with Laplace regression. For survival analysis, VA was categorized
as <80% (n = 135), or ≥80% of the predicted value (n = 125).
Results: Follow-up had a median duration of 2.7 years (interquartile range, 1.1 to 4.2 years). The crude mortality
rate was 27% in the whole sample, 36% in patients with VA < 80%, and 16% in those with VA ≥ 80%. The HR of
death was 2.3-fold higher in patients with VA <80% than in those with VA ≥80% (p = 0.002). After adjusting for age,
New York Heart Association class III-IV, cardiothoracic ratio >0.5, NT-proBNP, persistent atrial fibrillation, DLCO, COPD
comorbidity, use of beta-blockers and angiotensin converting enzyme inhibitors, the HR decreased to 1.9 but
remained statistically significant (p = 0.039). Two percent of the patients with VA < 80% died about 0.9 years earlier
than those with VA ≥80% (p = 0.033). The difference in survival time at the 20th percentile was 0.8 years.
Conclusions: VA is a significant, independent predictor of reduced survival in patients with systolic HF.
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Heart failure (HF) is a common clinical disorder carrying
significant morbidity and mortality [1,2]. Ventilatory im-
pairment is known to occur in patients with HF, and is
ascribed to factors such as heart enlargement, pulmo-
nary stiffness due to chronic interstitial edema, and
respiratory muscle dysfunction [3-7]. The coexistence of
chronic airflow obstruction may add to ventilatory dys-
function, and is believed to have a negative prognostic
impact in patients with chronic HF [8].* Correspondence: massimo.miniati@unifi.it
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reproduction in any medium, provided the orAs of now, most of the studies on the prognostic im-
pact of respiratory dysfunction in HF focused on simple
spirometry [9-14], with only a few exploring the ex-
change of gases across the alveolar-capillary membrane
[15,16].
Alveolar volume (VA) is the volume of air in the lung
available for gas exchange, and is currently measured by
the dilution of an inert gas during a single breath-hold
maneuver [17]. Due to the single-breath approach, such
measurement is sensitive to ventilatory disturbances. In
healthy subjects, VA equals total lung capacity (TLC)
measured by multiple-breath helium dilution. In subjects
with ventilatory impairment, VA is often much lowerLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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alveolar spaces [18].
We conducted a prospective, observational study
aimed at establishing the prognostic value of VA, as % of
the predicted value, in 260 consecutive patients with sys-
tolic HF. The outcome measure was all-cause mortality
over a median follow-up time of about three years.
Methods
Ethics statement
The protocol was approved by the local ethics commit-
tee (Comitato Etico, Azienda Ospedaliero-Universitaria
Pisana, Pisa, Italy). Before entering the study, the sub-
jects provided an informed written consent.
Sample
The study sample comprised 260 consecutive patients
with an established diagnosis of systolic HF. They were
hospitalized at the CNR Institute of Clinical Physiology
and “G. Monasterio” Foundation, Pisa, Italy, between
January 1, 2000 and December 31, 2007. The diagnosis
of HF was based on the Framingham criteria [19],
and the finding of a left ventricular ejection fraction
(LVEF) <50% at transthoracic echocardiography. Pa-
tients were excluded if they had active cancer, recent
(within 6 months) acute coronary syndromes, or pul-
monary arterial hypertension.
Study protocol
All the patients were evaluated under stable clinical con-
ditions, shortly before hospital discharge. Lung function
studies included the measurement of slow (SVC) and
forced vital capacity (FVC), forced expiratory volume in
one second (FEV1), and total lung capacity (TLC). At
least three spirometric measurements were obtained and
the highest values were chosen. Spirometry was per-
formed by experienced technologists in conformity with
the ATS/ERS standards [20]. The diagnosis of COPD
was based on clinical and spirometric criteria (post-
bronchodilator ratio of FEV1/SVC below the 5th per-
centile of predicted value) [21]. The degree of airflow
obstruction was categorized as mild, moderate, or severe
if FEV1 was >80%, between 80 and 50%, and <50% of
predicted, respectively. Ventilatory restriction was diag-
nosed if FEV1/SVC ratio was normal, and TLC below
the 5th percentile of predicted [21]. The diffusing cap-
acity of the lung for carbon monoxide (DLCO) was deter-
mined using the single-breath method in conformity
with ATS/ERS recommendations [17]. VA was measured
during the single-breath maneuver using helium as the
inert gas [17].
Postero-anterior and lateral digital chest radiographs
were obtained in all the subjects at the time of lung
function testing, and were examined by two of theauthors (MM, SM) for the presence of heart, pulmonary,
and pleural abnormalities. On the postero-anterior view,
we also measured the cardiothoracic ratio. This was
regarded as abnormal if >0.5. We measured the circu-
lating levels of hemoglobin, creatinine, and N-terminal
pro-hormone of B-type natriuretic peptide (NT-proBNP).
The latter was measured by an electrochemiluminescent
sandwich immonoassay using Elecsys 2010 analyser
(Roche Diagnostics, Germany) [22]. Medications pre-
scribed at the time of hospital discharge were also
recorded.Follow-up
The 260 patients were followed up until death or March
31, 2009, whichever occurred first. All the subjects were
seen periodically at the outpatient clinic of our institu-
tion. Whenever required, their family physicians were
also contacted. The cause of death was established by
reviewing medical records, autopsy findings, or death
certificates.Statistical analysis
Differences between groups were assessed by Fisher’s
exact test for the categorical variables, and by Mood’s
median test for the continuous variables. Continuous
variables in the text and in the tables are reported as
median and interquartile range (IQR). The association
between VA and survival was evaluated with two me-
thods: Cox proportional hazard regression to estimate
hazard ratio (HR) for the risk of death, and Laplace re-
gression to estimate the percentiles of survival time [23].
Survival percentiles may offer a comprehensive picture
of the covariate effects on survival time while over-
coming some of the known interpretational limitations
of HR [24]. The main exposure of interest was VA
which was categorized as <80% or ≥80% of the pre-
dicted value. Based on univariate analysis, the follow-
ing potential confounders were considered: tertiles of
age (≤61, 62-71, ≥72 years), New York Heart Associ-
ation (NYHA) class III-IV, cardiothoracic ratio >0.5,
DLCO as % predicted (split in two categories by the
median value in the sample), tertiles of NT-proBNP
(≤787, 788-2058, ≥2059 pg/mL), persistent atrial fibril-
lation, COPD comorbidity, use of beta-blockers, and
of angiotensin converting enzyme (ACE) inhibitors.
The crude and adjusted percentiles, and the hazard
ratios and associated 95% confidence intervals (CI)
are reported. The proportionality of the hazard in the
Cox regression was tested based on the Schoenfeld resid-
uals for each model separately. Two-tailed p-values <0.05
were considered statistically significant throughout. The
statistical analysis was performed with Stata version 11
(StataCorp, College Station, TX).
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Sample
The baseline characteristics of the study sample are
given in Table 1. Based on clinical and spirometric data,
COPD was diagnosed in 65 (25%) of 260 cases; airflow
obstruction was mild in 11 patients (17%), moderate in
41 (63%), and severe in 13 (20%). In the whole sample,
the median value of VA was 79% of predicted (IQR, 70
to 88%). There was a highly significant, inverse corre-
lation of VA with NT-proBNP (r = -0.21; p < 0.001) and





Age, years 68 (58–75)
Male gender 207 (80)
BMI, kg/m2 26 (24–29)
Current smoker 50 (19)
NYHA class III-IV 84 (32)
LVEF, % 32 (25–40)
Cardiothoracic ratio >0.5 162 (62)
NT-ProBNP, pg/mL 1302 (531–3028)
Hemoglobin, g/dL 13.7 (12.4–14.9)
Creatinine, mmol/L 101 (82–127)
FEV1, % predicted 87 (72–101)
DLCO, % predicted 70 (61–81)
COPD 65 (25)
Ventilatory restriction 53 (20)
Coronary artery disease 115 (44)
Hypertension 141 (54)
Persistent atrial fibrillation 51 (20)





Angiotensin receptor antagonists 75 (29)
Loop diuretics 225 (87)
Potassium sparing drugs 175 (67)
Warfarin 42 (16)
Implanted pace-maker 35 (13)
Implanted defibrillator 13 (5)
IQR = interquartile range. BMI = body mass index. NYHA = New York Heart
Association. LVEF = left ventricular ejection fraction. NT-proBNP = N-terminal
pro-hormone of B type natriuretic peptide. FEV1 = forced expiratory volume in
one second. DLCO = diffusing capacity of the lung for carbon monoxide.
COPD = chronic obstructive pulmonary disease. ACE = angiotensing
converting enzyme.borderline significant correlation with LVEF (r = +0.11;
p = 0.054).
Table 2 shows the characteristics of the study sample
spit by VA category. As compared with patients having
VA ≥ 80%, those with VA < 80% featured the following sta-
tistically significant differences: (a) older age; (b) higher
prevalence of NYHA class III-IV, abnormal cardiothoracic
ratio, persistent atrial fibrillation, COPD comorbidity,
and ventilatory restriction; (c) lower FEV1 and DLCO;
(d) higher levels of NT-proBNP. As regards medical
treatment, significantly less patients with VA < 80%
were prescribed beta-blockers and ACE-inhibitors, and
significantly more were on oral anticoagulants than those
with VA ≥ 80%.
Radiologic signs of interstitial lung edema were de-
tected in 16% of the patients with VA < 80% and in 3% of
those with VA ≥ 80% (p < 0.001). Similarly, small pleural
effusions prevailed significantly in the lower VA category
than in the other (24% vs 6%, p < 0.001), whereas no sta-
tistically significant difference was observed as regards
the prevalence of radiologic signs of emphysema (11% vs
7%, p = 0.293). None of the sampled patients had evi-
dence of overt lung fibrosis.
Survival analysis
Follow-up was completed in all the patients, and had a
median duration of 2.7 years (IQR, 1.1 to 4.2 years). The
crude mortality rate was 27% (69/260) in the whole sam-
ple, 36% (49/135) in patients with VA < 80%, and 16%
(20/125) in those with VA ≥ 80%. The causes of death
were: heart failure (n = 44), cancer (n = 9), respiratory
failure (n = 5), sudden death (n = 4), liver failure (n = 2),
sepsis (n = 2), multiple trauma (n = 2), and renal failure
(n = 1).
Figure 1 shows the estimated cumulative incidence of
death which was significantly higher in patients with
VA < 80% than in the others (p = 0.032). The mortality
curves are adjusted for age, NYHA class III-IV, cardio-
thoracic ratio >0.5, NT-proBNP, persistent atrial fibrilla-
tion, DLCO as % predicted, and COPD comorbidity.
Table 3 describes the regression estimates of the HR of
death for the two categories of VA. The unadjusted HR
of death in patients with VA < 80% was 2.3-fold higher
than in those with VA ≥ 80% (p = 0.002). After adjusting
for potential confounders, the HR of death decreased to
1.9 but remained statistically significant (p = 0.039).
Laplace regression estimates of the percentiles of
survival by VA category are displayed in Figure 2. They
are adjusted for age, NYHA class III-IV, cardiothoracic
ratio > 0.5, NT-proBNP, persistent atrial fibrillation,
DLCO as % predicted, and COPD comorbidity. Two
percent of the patients with VA < 80% died about
0.9 years earlier than those with VA ≥ 80% (p = 0.033).
The difference at the 20th percentile was 0.8 years.
Table 2 Study sample split by alveolar volume
Alveolar volume (% predicted)
Characteristic <80 (n = 135) ≥80 (n = 125) P-value
Age, years 71 (66–77) 64 (55–71) <0.001
Male gender 109 (81) 98 (78) 0.648
BMI, kg/m2 26 (24–29) 26 (23–30) 1.000
Current smoker 21 (16) 29 (23) 0.157
NYHA class III-IV 57 (42) 27 (22) <0.001
LVEF, % 30 (25–38) 33 (25–40) 0.710
Cardiothoracic ratio >0.5 93 (69) 69 (55) 0.029
NT-ProBNP, pg/mL 1607 (811–3878) 982 (297–2141) 0.003
Hemoglobin, g/dL 13.6 (12.5–14.7) 13.7 (12.4–15.0) 0.552
Creatinine, mmol/L 105 (82–137) 97 (82–114) 0.139
FEV1, % predicted 78 (65–87) 99 (90–109) <0.001
DLCO, % predicted 66 (53–75) 76 (68–92) <0.001
COPD 42 (31) 23 (18) 0.022
Ventilatory restriction 53 (39) 0 (0) <0.001
Coronary artery disease 66 (49) 49 (39) 0.134
Hypertension 75 (56) 66 (53) 0.709
Persistent atrial fibrillation 34 (25) 17 (14) 0.020
Prior stroke 10 (7) 11 (9) 0.821
Diabetes 44 (33) 38 (30) 0.790
Dyslipidemia 52 (39) 57 (44) 0.260
Beta-blockers 107 (79) 116 (93) 0.002
ACE-inhibitors 69 (51) 81 (65) 0.033
Angiotensin receptor antagonists 40 (30) 35 (28) 0.786
Loop diuretics 117 (87) 108 (86) 1.000
Potassium sparing drugs 84 (62) 91 (73) 0.085
Warfarin 28 (21) 14 (11) 0.043
Implanted pace-maker 20 (15) 15 (12) 0.589
Implanted defibrillator 5 (4) 8 (6) 0.398
Data are numbers (%), or medians (interquartile range). For abbreviations see Table 1.
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reduced VA.Discussion
The present study was designed to establish whether VA,
as percent of the predicted value, is a prognostic indica-
tor in systolic HF. Our results can be summarized thus:
(a) the cumulative incidence of death is significantly
higher in patients with VA < 80% predicted than in those
with VA ≥ 80%; (b) the estimated HR of death is about
two-fold greater among the patients in the lower VA
category, and remains significantly higher after adjusting
for relevant confounding variables; (c) as indicated by
Laplace regression, reduced VA is strongly associated
with early deaths.We found a significant, inverse correlation between
VA and cardiothoracic ratio. This suggests that heart
enlargement is a major determinant of reduced VA in
chronic HF. Generalized stiffness of the lung paren-
chyma may also contribute to diminish VA. Such re-
duced lung distensibility is due to chronic interstitial
edema, and pulmonary vascular remodeling that are
known to occur in long-standing HF [25].
We also observed that VA is significantly correlated
with the circulating levels of NT-proBNP, an established
prognostic biomarker of HF [2]. After adjusting for
NT-proBNP, the HR of death associated with reduced
VA remains statistically significant so indicating that
VA is an independent predictor of survival.
A number of studies investigated on simple spirometry
as a potential indicator of future cardiovascular events.
Figure 2 Laplace regression estimates of the 2nd and 20th
percentile of survival time in the sample split by alveolar
volume (VA) as % predicted (<80% vs ≥80%). Estimates are
adjusted for age, NYHA class III-IV, cardiothoracic ratio >0.5,
NT-proBNP, persistent atrial fibrillation, DLCO as % predicted, and
COPD comorbidity.
Figure 1 Estimated cumulative mortality in the study sample
split by alveolar volume (VA) as % predicted: VA <80% (red step
curve); VA ≥80% (blue step curve). Estimates are adjusted for age,
NYHA class III-IV, cardiothoracic ratio >0.5, NT-proBNP, persistent
atrial fibrillation, DLCO as % predicted, and COPD comorbidity.
P-value by log-rank test = 0.032.
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observed that FVC is a significant, independent pre-
dictor of cardiovascular morbidity and mortality in al-
legedly healthy subjects [9]. Later, Kannel et al. reported
that FVC is a predictor of subsequent cardiac failure in
individuals with coronary artery disease and left ven-
tricular hypertrophy [10].
In recent years, there has been increasing interest in
evaluating the prognostic impact of COPD comorbidity
in patients with chronic HF. Mascarenhas et al. [11]
conducted a retrospective study in 186 patients with sys-
tolic HF, and found no significant association between
having COPD and all-cause mortality (HR 1.40, 95% CI
0.88 to 2.44). Only severe airflow obstruction (FEV1 < 50%
of predicted value) appeared to be a predictor of reduced
survival (HR 2.10, 95% CI 1.05 to 4.22) [11]. In 527
patients with a clinical diagnosis of HF, Iversen et al.
reported that FEV1 has independent prognostic value (HR
0.86 per 10% change with respect to the predicted value,
p < 0.001) [12]. By contrast, Macchia et al. estimated an
adjusted HR of death of 0.77 (95% CI, 0.37 to 1.58)
in patients with systolic HF and concomitant chronic
airway obstruction, suggesting that COPD has no signi-
ficant bearing on survival [13]. The three studies differTable 3 Estimated hazard ratios of death by alveolar
volume category
VA <80% versus VA ≥80%
Model Hazard ratio 95% CI P-value
1 2.31 (1.37–3.90) 0.002
2 1.90 (1.03–3.50) 0.039
VA = alveolar volume (as % predicted). CI = confidence interval.
Model 1: unadjusted.
Model 2: adjusted for age, NYHA class III-IV, NT-proBNP, cardiothoracic ratio
>0.5, persistent atrial fibrillation, DLCO as % predicted, COPD comorbidity, use
of beta-blockers and of ACE-inhibitors.
For abbreviations, see Table 1.substantially for proportion of severe airflow obstruction,
NYHA class III-IV, and duration of follow-up, and this
may explain the inconsistent results obtained as regards
the prognostic impact of COPD in HF.
Recently, Miniati et al. reported that a reduction of
FEV1 – be it due to airflow obstruction or ventilatory
restriction – is a significant, independent predictor of
reduced survival in 439 patients with systolic HF [14]. In
that study, the adjusted HR of death was 1.8-fold higher
in patients with FEV1 <80% predicted as compared with
those having FEV1 ≥80% [14].
As of now, limited data is available on the prognostic
relevance of lung function tests other than spirometry. It
is well established that chronic HF brings about exten-
sive remodeling of the pulmonary intra-alveolar vessels
and interstitium [26], which may hamper the exchange
of gases across the alveolar-capillary barrier [15]. In 106
patients with systolic HF, Guazzi and coworkers reported
that alveolar-capillary membrane conductance of less
than 24.7 mL/min/mmHg is significantly and independ-
ently associated with a worse outcome [16]. Partitioning
of lung diffusing capacity into its membrane and capil-
lary blood volume components requires the determina-
tion of DLCO at two different concentrations of oxygen
in the inspired test bolus [15,16]. This technique is sel-
dom used in routine clinical practice.
VA represents an estimate of the lung gas volume into
which CO is distributed and, therefore, is critical in the
measurement of DLCO with the single-breath approach
[17]. In the presence of uneven distribution of ventila-
tion, due to altered lung distensibility or airflow obstruc-
tion, VA primarily reflects the volume of the airspaces
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the breath-hold time [17]. The estimated volume can,
therefore, be regarded as reflecting the size of the
well-ventilated lung regions. As shown in Table 2,
spirometrically determined ventilatory restriction, was
present in only 53 (39%) of 135 patients with VA <80%
predicted. So, we believe that measuring VA may add valu-
able information as regards lung function assessment in
patients with systolic HF.
Undoubtedly, factors other than VA affect the lung dif-
fusing capacity, including the physical properties of the
alveolar membrane, the density of alveolar capillaries,
and the hemoglobin concentration [17]. Thus, in multi-
variate analysis, we incorporated DLCO among the po-
tential confounding variables. After adjustment, the HR
of death associated with the lower VA category remained
statistically significant.
Study limitations
First, we only studied patients with systolic HF, so our
findings may not apply to patients with isolated diastolic
heart dysfunction. Second, our data originated from a
single referral center, and included a relatively small
number of cases. Broader multicenter prospective stu-
dies are needed to firmly establish the prognostic value
of VA in HF. Third, we obtained a single determination
of VA. So, it would of interest to evaluate the effect of
cardiovascular and pulmonary medications on VA size
over time, and to test whether improvement in VA is asso-
ciated with a better oucome in patients with chronic HF.
Conclusions
The present study indicates that VA, as percent of the
predicted value, is a significant, independent predictor of
reduced survival in patients with systolic HF.
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